

Status: Currently Official on 15-Feb-2025

Official Date: Official Prior to 2013

Document Type: USP Monographs

DocId: GUID-8503E5FE-54E7-44FD-8A77-4A14197C4139_1_en-US

DOI: https://doi.org/10.31003/USPNF_M35940_01_01

DOI Ref: b13iw

© 2025 USPC

Do not distribute

Griseofulvin Oral Suspension

DEFINITION

Griseofulvin Oral Suspension contains NLT 90.0% and NMT 115.0% of the labeled amount of griseofulvin ($C_{17}H_{17}ClO_6$). It contains one or more suitable colors, diluents, flavors, preservatives, and wetting agents.

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

• PROCEDURE

Solution A: 100 mg/mL of sodium chloride in water

Mobile phase: Acetonitrile, tetrahydrofuran, and water (35:5:60). Degas for 5 min before use, and stir continuously during use.

Standard stock solution: 1.25 mg/mL of [USP Griseofulvin RS](#) in methanol

Standard solution: 0.125 mg/mL of [USP Griseofulvin RS](#) in *Mobile phase* from the *Standard stock solution*

Sample stock solution: Nominally 1.25 mg/mL of griseofulvin prepared as follows. Transfer a measured volume of Oral Suspension, freshly mixed and free from air bubbles and equivalent to 125 mg of griseofulvin, to a glass-stoppered, 50-mL centrifuge tube. Add 20 mL of methylene chloride and 20 mL of *Solution A*. Insert the stopper into the tube, and mix by rotating the tube for 10 min. Separate the phases by centrifugation, carefully remove the lower methylene chloride layer with a needle and syringe, and filter through methylene chloride-prerinsed anhydrous sodium sulfate into a 100-mL volumetric flask. Repeat the extraction with two additional 20-mL portions of methylene chloride, combining the extracts in the volumetric flask. Dilute with methylene chloride to volume.

Sample solution: Nominally 0.125 mg/mL of griseofulvin prepared as follows. Transfer 5.0 mL of *Sample stock solution* to a 50-mL volumetric flask, and evaporate on a steam bath under a stream of nitrogen to dryness. Transfer 4.0 mL of *Mobile phase* to the flask, swirl to dissolve the residue, and dilute with *Mobile phase* to volume.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; packing L10

Flow rate: 1 mL/min

Injection volume: 20 μ L

System suitability

Sample: *Standard solution*

Suitability requirements

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of griseofulvin ($C_{17}H_{17}ClO_6$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Griseofulvin RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of griseofulvin in the *Sample solution* (mg/mL)

P = potency of griseofulvin in [USP Griseofulvin RS](#) ($\mu\text{g}/\text{mg}$) F = conversion factor, 0.001 mg/ μg **Acceptance criteria:** 90.0%–115.0%**PERFORMANCE TESTS**

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements for oral suspension packaged in single-unit containers
- [DELIVERABLE VOLUME \(698\)](#): Meets the requirements

SPECIFIC TESTS

- [pH \(791\)](#): 5.5–7.5

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.
- **LABELING:** The label indicates that the griseofulvin contained is known as griseofulvin (microsize).
- [USP REFERENCE STANDARDS \(11\)](#)

[USP Griseofulvin RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
GRISEOFULVIN ORAL SUSPENSION	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-8503E5FE-54E7-44FD-8A77-4A14197C4139_1_en-US

DOI: https://doi.org/10.31003/USPNF_M35940_01_01

DOI ref: [b13iw](#)